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Abstract
Electroconvulsive therapy (ECT) is a highly effective and fast-acting treatment for depression. Despite a long history
of clinical use, its mechanism of action remains poorly understood. Recently, a novel cellular mechanism of
antidepressant action has been proposed: the phenotype of mature brain neurons is transformed to immature-like one
by antidepressant drug treatments. We show here that electroconvulsive stimulation (ECS), an animal model of
ECT, causes profound changes in maturation-related phenotypes of neurons in the hippocampal dentate gyrus of
adult mice. Single ECS immediately reduced expression of mature neuronal markers in almost entire population
of dentate granule cells. After ECS treatments, granule cells showed some of physiological properties characteristic of
immature granule cells such as higher somatic intrinsic excitability and smaller frequency facilitation at the detate-to-CA3
synapse. The rapid downregulation of maturation markers was suppressed by antagonizing glutamate NMDA receptors,
but not by perturbing the serotonergic system. While single ECS caused short-lasting effects, repeated ECS
induced stable changes in the maturation-related phenotypes lasting more than 2 weeks along with enhancement of
synaptic excitation of granule cells. Augmentation of synaptic inhibition or blockade of NMDA receptors after repeated
ECS facilitated regaining the initial mature phenotype, suggesting a role for endogenous neuronal excitation in
maintaining the altered maturation-related phenotype probably via NMDA receptor activation. These results suggest that
brief neuronal activation by ECS induces “dematuration” of the mature granule cells and that enhanced
endogenous excitability is likely to support maintenance of such a demature state. The global increase in
neuronal excitability accompanying this process may be relevant to the high efficacy of ECT.
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Background
Granule cells (GCs) in the hippocampal dentate gyrus
(DG) have been implicated in the pathophysiological
mechanisms of neuropsychiatric disorders including
depression and schizophrenia, and have been suggested
to be an important target for both pharmacological and
physical therapeutic treatments [1–6]. We have recently
demonstrated distinct changes in the molecular and
physiological phenotypes of GCs as a candidate cellular
mechanism of action of a selective serotonin reuptake
inhibitor (SSRI): The SSRI fluoxetine can transform
several mature features of GCs in the adult mouse DG
[7]. The fluoxetine treatment strongly reduced expres-
sion of mature GC markers, induced active somatic
membrane properties resembling immature GCs, and
decreased short-term plasticity at the dentate-to-CA3
synaptic connection that characterizes the mature dentate-
to-CA3 signal transmission. These changes cannot be ex-
plained simply by an increase in newly generated immature
GCs, but are most likely characterized as “dematuration” of
mature GCs [7].
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These changes in the maturation-related phenotypes
of GCs were not observed after short-term treatment of
fluoxetine, and the efficacy of fluoxetine is quite variable
among individual mice [7, 8]. Such unstable and unpre-
dictable nature of the effects of fluoxetine well mimics
common clinical observations in antidepressant medica-
tion such as delayed emergence of therapeutic effects
and treatment resistance [9]. In a mouse model of de-
pression and anxiety, the changes in the maturation-
related phenotypes of GCs can be induced at a serum
concentration of fluoxetine close to that seen in patients
during fluoxetine medication [10], suggesting clinical
relevance of these changes in GCs. Therefore, we pro-
posed that modifications of maturation-related pheno-
types in mature neurons may cause some beneficial or
therapeutic effects of SSRIs by reinstating cellular func-
tions of immature neurons. This proposal has been
supported by demonstration of similar SSRI-induced
changes in the neuronal maturation status in other
brain regions [11, 12].
In addition to antidepressant drugs, electroconvulsive
therapy (ECT) has been used to treat depression. ECT
was originally devised for treating psychosis in the 1930s
[13] and is currently considered as the most effective
treatment for depression [14]. ECT has fast-acting anti-
depressant effects and is effective in most of medication-
resistant patients. Despite a long history of clinical use,
the mechanism of action of ECT still remains poorly
understood. In particular, it is unknown how distinct
types of treatments, antidepressant drug medication and
ECT, converge on the same antidepressant action. In
rodents, ECT-like stimulation has been shown to re-
duce immunoreactivity for the calcium binding protein
calbindin in the DG [15, 16]. Calbindin has been con-
sidered as a marker for mature GCs, because its expres-
sion is not seen in newly generated GCs at the cell age
of 10 days or less and is established in about 4 weeks
[17]. A reduction of calbindin expression is one of char-
acteristic features of demature GCs in SSRI-treated
mice. Therefore, it is possible that ECT-like stimulation
can also induce dematuration of GCs, possibly in a
more rapid and consistent manner than SSRI treat-
ments. To test this hypothesis, in the present study, we
examined how electroconvulsive stimulation (ECS), an
animal model of ECT, regulates maturation-related
phenotypes of the mature GCs in the adult mouse DG.
Results
Downregulation of mature granule cell markers by ECS
The matured state of GCs is characterized by several dis-
tinct molecular and physiological features [18, 19], and
chronic SSRI treatment can change some of such features
to immature-like ones [7, 8, 10, 20]. We first examined
the effect of ECS on the expression of the mature GC
marker calbindin in adult mice and found that expression
of the gene encoding calbindin (Calb1) in the DG was en-
tirely reduced by a single ECS (Fig. 1a), which is consistent
with the previous observations of the reduced calbindin-
like immunoreactivity after ECS [15, 16]. A single and
repeated ECS (11 times over a period of 3 weeks) reduced
the expression of Calb1 and that of the gene encoding
tryptophan 2,3-dioxygenase (Tdo2), another mature GC
marker [7, 21], at 6 h after the stimulation (Fig. 1b). After
repeated ECS, the gene expression of desmoplakin (Dsp)
and interleukin-1 receptor type 1 (Il1r1), which show de-
velopmental expression profiles similar to those of Calb1
and Tdo2 [7], was also reduced (Fig. 1c). The global reduc-
tion of calbindin expression after repeated ECS was
confirmed at the protein level (Fig. 1d, e). In contrast, the
same treatment did not affect the expression of the neur-
onal marker NeuN (Fig. 1d) or PSD-95 (Fig. 1e), which
excludes the possibility that ECS caused non-specific
damage on GCs. Repeated ECS upregulated the expres-
sion of calretinin, a marker of immature GCs at the early
post-mitotic stage, in the subgranular zone, probably via
increased adult neurogenesis. The majority of the NeuN-
positive and calbindin-negative GCs in the DG did not
express calretinin after ECS (Fig. 1d). We next examined
the effect of ECS on the stimulus-induced expression of
immediate early genes (IEGs), which is an index of the
maturity of activity-dependent neuronal responsiveness in
vivo [18, 19, 22]. While a single ECS induced robust
expression of the IEG c-fos in the majority of GCs, this c-
fos expression in GCs was strongly suppressed after
repeated ECS (Fig. 2a). Repeated ECS significantly sup-
pressed robust induction of other IEGs, Gadd45b, Nr4a1,
Arc, and Egr1, in the DG at 1 h after the stimulation
(Fig. 2b). We further compared gene expression profiles at
1 h after the stimulation between single ECS-treated and
repeated ECS-treated DGs. Among genes that showed sig-
nificant changes by a single ECS treatment (329 increased
genes and 1,090 decreased genes), more than 300 genes
(195 increased genes and 117 decreased genes) showed
reduced responsiveness after repeated ECS treatments
(Fig. 2c). Functional gene ontology classification revealed
that the genes that showed reduced responsiveness after
repeated ECS are strongly associated with cellular
responses to a variety of stimuli including cAMP, hor-
mones, and cytokines as well as regulation of transcription
(Additional file 1: Table S1-S2).
ECS-treated granule cells partially exhibit physiological
properties resembling immature neurons
Above results demonstrate that ECS strongly downregu-
lates several markers for mature GCs, which resembles
the effects of chronic SSRI treatments on the dentate GCs
[7, 10, 20]. We then examined the electrophysiological
properties of ECS-treated GCs. Immature GCs show
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higher somatic excitability, higher input resistance, and
more depolarized resting membrane potentials than ma-
ture GCs [23, 24]. Repeated ECS increased the somatic
excitability of GCs and reduced their resting membrane
potentials, but had no significant effect on input resistance
(Fig. 3a, b). We next analyzed the synaptic transmission
between the GC axon mossy fibers (MFs) and the CA3
pyramidal cells (Fig. 3c). Although the MF synapse in
adult mice is characterized by strong frequency facilita-
tion, a form of presynaptic short-term plasticity, the im-
mature MF synapse in juvenile mice exhibits greatly
reduced frequency facilitation [7, 25]. While repeated ECS
had no significant effect on the basal synaptic efficacy
(Fig. 3d, e), it consistently reduced the frequency facilita-
tion of excitatory postsynaptic potentials (EPSPs) at the
MF synapse to a juvenile level (Fig. 3f, g). Therefore, ECS-
treated GCs showed some of physiological properties
characteristic of immature GCs.
ECS-treated mice share gene expression changes in DG
with SSRI-treated mice and genetically modified mice
with altered GC maturation
The above results suggested that ECS and SSRI have
similar effects on the phenotype of GCs. To further address
this point, we next compared a gene expression profile
between chronic SSRI- and repeated ECS-treated DGs.
Among 3,531 genes that showed significant changes by
either ECS- or SSRI-treatment, 660 genes showed signifi-
cant increases and 670 genes showed significant decreases
by both ECS- and SSRI-treatment (Fig. 4a, b). Significant
correlation was identified in the gene expression change
between ECS-treated DG and SSRI-treatment DG (r = 0.76,
p < 0.0001). Functional gene ontology classification revealed
that the genes that showed significant increases by both
treatments are strongly associated with cholesterol meta-
bolic process, nervous system development, and neuron
projection development (Table 1). The genes that showed
significant decreases by both treatments also showed a
strong association with nervous system development
(Table 2). In contrast, the genes that were not com-
monly changed are less associated with neuronal func-
tions (Additional file 1: Table S3-S6). These results
suggest that repeated ECS and chronic SSRI induce a
similar change in the phenotypes of GCs, especially in
those related to neuronal functions and development,
in the adult DG.
We have previously shown that adult dentate GCs stay in
an immature-like state in mice heterozygous for α-calcium/
Fig. 1 Alteration of GC maturation stage markers in the DG after ECS. a, Representative images of in situ hybridization of Calb1 at 6 h after single
ECS or sham (CNT) treatment. Scale bars: upper 1 mm, lower 200 μm. b, The relative expression of Calb1 and Tdo2 at 6 h after the indicated number of
ECS (Dunnett’s test following one-way ANOVA: F(3,12) = 69.72, *** P < 0.001 for Calb1, F(3,12) = 67.15, *** P < 0.001 for Tdo2). c, The relative expression of
Dsp and Il1r1 after 11 ECS sessions (t(6) = 5.733, ** P < 0.01 for Dsp, t(6) = 4.418, ** P < 0.01 for Il1r1). d, Representative images of immunoreactivity for
NeuN, calbindin, and calretinin in DG at 24 h after 11 ECS sessions. GCL: granule cell layer. Scale bar: 20 μm. e, Immunoblot detections of
reduced calbindin D-28 K expression (t(8) = 6.899, *** P < 0.001) and intact PSD-95 expression in DG (t(8) = 1.082, P = 0.31). The n number is
given in graph. Data are presented as means ± SEM
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calmodulin-dependent protein kinase II (α-CaMKII
hetero KO) [2] and in Schnurri-2 knockout (Shn-2
KO) mice [26]. To further characterize the phenotype
of ECS-treated GCs, we next compared the pattern of
the gene expression change in the ECS-treated DG
with that in the hippocampus from these mutant mice.
The genes that showed statistically significant and
more than 1.2-fold changes were plotted in Fig. 4c.
Significant correlation was identified in the gene ex-
pression change between ECS-treated DG and Shn-2
KO hippocampus (r = 0.65, p < 0.0001) and between
ECS-treated DG and α-CaMKII hetero KO hippocam-
pus (r = 0.61, p < 0.0001). Among the 30 genes most
up- or down-regulated (15 genes each) by both ECS-
and SSRI-treatment, the expression for Calb1, Tdo2,
Frzb, Batf3, and Grp was commonly regulated in the
hippocampus of Shn-2 KO mice and α-CaMKII hetero
KO mice (Tables 3 and 4). These results suggest that
the ECS-treated GCs share the phenotype with
immature-like GCs of Shn-2 KO mice and α-CaMKII
hetero KO mice.
Involvement of NMDA receptor-dependent signaling in
the rapid downregulation of maturation markers by ECS
Unlike SSRI-induced changes in the maturation-related
phenotypes, which are not observed after short-term
drug treatments [7], the ECS-induced changes in GCs,
especially downregulation of mature GC markers, rap-
idly developed (Fig. 1b). We next explored the mech-
anism involved in this rapid effect of ECS. We first
examined the involvement of the serotonin type 4
receptor (5-HT4R) in downregulation of Calb1 expression
in GCs, because this receptor plays a key role in the SSRI-
induced change in the maturation-related phenotypes of
GCs [7, 20]. However, neither deficiency of 5-HT4R nor a
lesion of the central serotonergic neurons induced by 5,7-
dihydroxytryptamine (5,7-DHT) affected the reduction of
Calb1 expression by a single ECS (Fig. 5a, b). Therefore,
the serotonergic system is not required for the rapid
downregulation of the maturation marker by ECS.
We then examined the involvement of an N-methyl-
D-aspartate receptor (NMDAR) using D-(-)-2-amino-
5-phosphonopentanoic acid (D-AP5), an NMDAR antagonist.
Fig. 2 Altered stimulus-induced gene expression in DG after repeated ECS. a, Left: representative images of immunoreactivity for c-fos and NeuN
at 2 h after the last ECS. Scale bar, 100 μm. Right: the sham (CNT) treatment or ECS was applied to naive mice or mice treated with 10 times of
chronic ECS (cECS). The expression of Fos at 1 h after the last treatment was examined (Tukey’s test following one-way ANOVA: F(3,12) = 35.77, ***
P < 0.001). b, The relative expression of other IEGs (Gadd45b, Nr4a1, Arc, and Egr1) mRNA at 1 h after the last ECS or control treatment (Tukey’s test
following one-way ANOVA: F(3,12) = 31.16, *** P < 0.001 for Gadd45b, F(3,12) = 38.36, *** P < 0.001 for Nr4a1, F(3,12) = 33.39, *** P < 0.001 for Arc,
F(3,12) = 39.82, ** P < 0.01, *** P < 0.001 for Egr1). c, The number of genes that showed a significant increase or decrease by a single ECS-treatment is
represented in bars. The three groups that were categorized according to expression change by repeated ECS were color-coded. The n number is
given in graph. Data are presented as means ± SEM
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Intracerebroventricularly injected D-AP5 attenuated
the reduction of Calb1 and Tdo2 expression levels by a
single ECS (Fig. 5c). As NMDAR activation upregulates
expression of many genes in the DG, gene induction
and subsequent de novo protein synthesis may be ne-
cessary for ECS-induced downregulation of mature GC
markers. As expected, pretreatments with cyclohexi-
mide, a protein synthesis inhibitor, attenuated the
reduction of Calb1 and Tdo2 by a single ECS (Fig. 5d).
These results suggested that protein synthesis and
NMDAR activation are important for the rapid down-
regulation of mature GC markers by ECS.
Long-lasting phenotypic change in granule cells after
repeated ECS
We next examined the maintenance of the change in
maturation-related phenotypes of GCs after ECS. Al-
though a single ECS robustly reduced the expression of
Calb1 and Tdo2 in the DG at 6 h after ECS, the expres-
sion levels returned toward control levels within 24 h
(Fig. 6a). In contrast, the reduction of Calb1 and Tdo2
expression levels was maintained at least for 14 days
after repeated ECS (Fig. 6b). Similarly, while the reduction
of frequency facilitation at the MF synapse was transient
after 3 times of ECS, the reduction of frequency facilitation
Fig. 3 Immature-like functional properties of GC soma and output synapse after ECS treatment. a, Membrane potential changes (upper) induced
by depolarizing currents (lower) in GCs. Scale bars: 100 ms, 20 mV, 40 pA. b, Left: the threshold current intensity required to evoke a single spike
(t(53) = 2.157, * P =0.0356). Center: resting membrane potential (t(48) = 3.475, ** I = 0.0011, Student’s t-test with Welch’s correction). Right: input
resistance. The number (n) represents the number of cells. c, A diagram showing the electrode arrangement for recording field EPSPs at the
MF-CA3 synapse. d, No significant change in the input-output relationship at the MF synapse. Left: The relationship between field EPSP and
fiber volley amplitude was examined by changing stimulus intensities. Right: The slope value of regression line is shown (t(10) = 0.9684, P =
0.3557). The n number represents the number of slices. e, No significant change in MF field EPSP to fiber volley ratios at the baseline stimulus
intensity (t(10) = 0.9324, P = 0.3731). f, Reduction of 1-Hz frequency facilitation at the MF synapse after repeated ECS. Inset: sample recordings of
MF field EPSPs during baseline and 1-Hz stimulation. Scale bars: 10 ms, 0.5 mV. g, Reduction of frequency facilitation at the MF synapse after
ECS repeated twice or more times (ECS × 2, t(7) = 4.364, ** P = 0.0033; ECS × 11, t(14) = 8.832, *** P < 0.001). Both individual (grey) and mean data
(red) are shown for ECS-treated groups. The number (n) is shown in the graph. Data are presented as means ± SEM
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was maintained more than 28 days after 11 times of ECS
(Fig. 6c). The deficiency of 5-HT4R did not affect the re-
duction of Calb1 expression at 14 days after repeated ECS
(Fig. 6d), indicating that 5-HT4R is not required for the
long-lasting phenotypic change of GCs caused by ECS. We
also examined whether the long-lasting reduction of Calb1
expression in GCs depends on newly generated neurons.
Cranial X-ray irradiation mostly depleted the staining of
doublecortin, a marker for early immature GCs, even after
repeated ECS (Fig. 6f). In these X-ray-irradiated mice, the
reduction of Calb1 expression was normally observed at
14 days after repeated ECS (Fig. 6e). Taken together, these
results suggested that brief neuronal activation by ECS
rapidly changed the maturation-related phenotypes in
mature GCs, and that repeated treatments could
convert the transient phenotypic change into a robust
long-lasting one.
Fig. 4 Shared gene expression changes in repeated ECS-treated DG,
chronic SSRI-treated DG and hippocampus of mutant mice with
altered DG maturation. a, Scatter correlation graph of gene expression
changes [log2(fold-change)] between repeated ECS-treated and
chronic SSRI-treated DGs. The gene probes (3,531) that showed
significant changes by either ECS- or SSRI-treatment in microarray
analysis are shown. The eight groups that were categorized according
to expression change by ECS and/or SSRI treatment were color-coded.
b, The number of genes that showed significant expression changes
by either ECS- or SSRI-treatment are represented in a Venn diagram.
The color corresponds to that in (a). c, Scatter correlation graph
illustrating the fold change for gene expression levels in the DG
from repeated ECS-treated mice, the hippocampus from Shn-2
KO mice (558 gene probes, left), and the hippocampus from
αCaMKII hetero KO mice (190 gene probes, right). The genes that
showed statistically significant and more than 1.2-fold changes in
both the DG from ECS-treatment mice and the hippocampus
from mutant mice were selected
Table 1 Functional classification on the basis of the gene
ontology (GO) terms
Increased change by both ECS- and SSRI-treatment (660 probes)
GO number GO term No. P value
GO:0008203 cholesterol metabolic process 16 9.8E-09
GO:0016126 sterol biosynthetic process 10 1.1E-08
GO:0008202 steroid metabolic process 15 3.5E-08
GO:0006695 cholesterol biosynthetic process 9 1.3E-06
GO:0006694 steroid biosynthetic process 11 4.4E-06
GO:0007399 nervous system development 26 2.1E-05
GO:0010977 negative regulation of neuron
projection development
10 4.1E-05
GO:0061564 axon development 5 5.3E-05
GO:0010976 positive regulation of neuron
projection development
14 7.6E-05
GO:0042493 response to drug 24 1.2E-04
GO:0051591 response to cAMP 9 1.4E-04
GO:0009790 embryo development 10 2.2E-04
GO:0006950 response to stress 7 2.3E-04
GO:0001649 osteoblast differentiation 12 2.4E-04
GO:0031668 cellular response to extracellular
stimulus
6 2.8E-04
GO:0034097 response to cytokine 10 3.5E-04
GO:0007568 aging 15 3.6E-04
GO:0030154 cell differentiation 38 3.8E-04
GO:0009968 negative regulation of signal
transduction
8 4.4E-04
GO:0007155 cell adhesion 27 4.9E-04
GO:0006629 lipid metabolic process 26 5.1E-04
GO:0007565 female pregnancy 10 5.4E-04
GO:0043065 positive regulation of apoptotic
process
21 6.1E-04
GO:0043627 response to estrogen 9 7.6E-04
GO:0007179 transforming growth factor beta
receptor signaling pathway
9 8.3E-04
GO:0043407 negative regulation of MAP
kinase activity
7 8.4E-04
GO:2001237 negative regulation of extrinsic
apoptotic signaling pathway
7 9.5E-04
GO:0010628 positive regulation of gene expression 23 9.6E-04
The gene probes (660 probes) showed significantly increased change by both
ECS- and SSRI-treatment were selected. P-value was calculated by a modified
Fisher’s exact test. Highly associated gene ontology terms (P < 0.001)
were represented
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Role of GABAergic signaling in reversal of long-lasting
phenotypic change
Since activation of excitatory synaptic transmission by
ECS is important for the change in the maturation-related
phenotype of GCs, we next examined a possibility that
GABAergic inhibitory synaptic transmission could play a
role in modulating this process. Diazepam, a positive allo-
steric modulator of GABAA receptor, was administered
during and/or after the ECS treatment period. Chronic
diazepam treatment had no significant effect on frequency
facilitation at the MF synapse in control mice (Fig. 7a),
suggesting a lack of effects on the mature state of GCs. In
diazepam-treated mice, however, the long-lasting reduc-
tion of frequency facilitation was attenuated at 14 days
after repeated ECS (Fig. 7b), and the decreased expression
of mature GC markers, Calb1 and Tdo2, was significantly
reversed at 14 days after repeated ECS (Fig. 7c). Diazepam
applied only during the period of ECS treatments was
similarly effective in attenuating the reduction of fre-
quency facilitation at 14 days after repeated ECS (Fig. 7d).
Diazepam applied only after the period of ECS treatments
partially, but significantly, reversed the reduction of fre-
quency facilitation (Fig. 7e). Thus, enhanced GABAergic
inhibition prevents the establishment of the lasting changes
in the maturation-related phenotype.
Increased synaptic activation of granule cells after
repeated ECS
Although repeated ECS increased somatic excitability of
GCs (Fig. 3b), this effect was relatively small. Since neur-
onal excitation depends on synaptic excitation/inhibition
(E/I) balance as well, we examined the effect of ECS on
excitation of GCs evoked by stimulation of synaptic inputs.
The medial perforant path (MPP) input to GCs was stimu-
lated, and evoked EPSPs and GC population spikes were
recorded in the GC layer (Fig. 8a). In ECS-treated mice, the
coupling between EPSPs and population spikes was signifi-
cantly enhanced (Fig. 8b). The GABAA receptor antagonist
picrotoxin abolished the difference in the EPSP-spike coup-
ling between control and ECS-treated mice (Fig. 8c). Thus,
Table 2 Functional classification on the basis of the gene
ontology (GO) terms
Decreased change by both ECS- and SSRI-treatment (670 probes)
GO number GO term No. P value
GO:0007399 nervous system development 26 5.12E-05
GO:0045944 positive regulation of transcription from
RNA polymerase II promoter
50 7.54E-05
GO:0016310 phosphorylation 33 4.24E-04
GO:0007169 transmembrane receptor protein tyrosine
kinase signaling pathway
11 4.45E-04
GO:0070498 interleukin-1-mediated signaling pathway 5 4.63E-04
GO:0008284 positive regulation of cell proliferation 30 5.84E-04
GO:0071277 cellular response to calcium ion 8 6.06E-04
GO:0006468 protein phosphorylation 31 7.05E-04
GO:0048511 rhythmic process 12 8.55E-04
The gene probes (670 probes) showed significantly decreased change by both
ECS- and SSRI-treatment were selected. P-value was calculated by a modified
Fisher’s exact test. Highly associated gene ontology terms (P < 0.001)
were represented
Table 3 Most up-regulated genes by ECS treatment among








1427683_at Egr2 5.9 1.5 n.c. n.c.
1422134_at Fosb 5.5 1.9 n.c. n.c.
1423100_at Fos 5 1.2 n.c. n.c.
1448594_at Wisp1 3.8 3.4 1.2 n.c.
1418687_at Arc 3.7 2.6 n.c. n.c.
1425671_at Homer1 3.6 1.4 n.c. 0.7
1418930_at Cxcl10 3.4 3.9 n.c. n.c.
1453076_at Batf3 3.4 2.5 2.4 1.1
1420720_at Nptx2 3.2 3.3 n.c. 1.3
1427038_at Penk1 3.1 3.4 n.c. 0.8
1417933_at Igfbp6 3.1 2.9 n.c. 0.4
1436563_at 4932441J04Rik 3.1 1.2 0.8 n.c.
1417262_at Ptgs2 3.0 1.4 n.c. 0.6
1424525_at Grp 2.9 3.7 1.8 1.6
1419127_at Npy 3.0 2.7 n.c. n.c.
Table 4 Most down-regulated genes by ECS treatment among








1450803_at Ntf3 −4.0 −3.3 −1.9 n.c.
1426980_s_at E130012A19Rik −3.5 −2.3 n.c. n.c.
1419663_at Ogn −3.4 −3.0 −1.9 n.c.
1425179_at Shmt1 −2.9 −1.5 −0.7 n.c.
1448424_at Frzb −2.4 −1.3 −1.1 −0.9
1419093_at Tdo2 −2.2 −2.8 −3.8 −3.4
1417858_at Rasal1 −2.0 −0.8 n.c. n.c.
1452114_s_at Igfbp5 −2.0 −0.9 −1.1 n.c.
1421595_at 9630031F12Rik −2.0 −1.9 −1.2 −0.3
1460203_at Itpr1 −1.9 −1.9 −1.0 n.c.
1448738_at Calb1 −1.9 −2.4 −2.4 −0.9
1420401_a_at Ramp3 −1.8 −1.9 n.c. n.c.
1424214_at 9130213B05Rik −1.7 −0.8 n.c. 0.19
1435162_at Prkg2 −1.7 −0.8 −0.6 n.c.
1449571_at Trhr −1.7 −1.0 n.c. n.c.
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the enhanced synaptic excitability observed after ECS is
largely due to a change in synaptic E/I balance toward exci-
tation. Using whole-cell recording, we confirmed that the
amplitude of the evoked inhibitory postsynaptic currents
(IPSCs), relative to the excitatory postsynaptic currents
(EPSCs), was significantly reduced in ECS-treated GCs
(Fig. 8d). The EPSP-spike coupling remained enhanced at
14 days after 11 times of ECS (Fig. 8e). These results
demonstrated that ECS causes a sustained increase in
synaptic excitability in the GCs.
This continuous enhancement of synaptic activation in
GCs through, and also beyond, the period of ECS treat-
ments suggests a possible involvement of endogenous
neuronal excitation during the non-stimulated period in
the establishment of the lasting change in the maturation-
related phenotype of GCs. To test this possibility, we
examined the effect of an NMDAR antagonist applied
during the inter-stimulus period. The NMDAR antag-
onist, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic
acid (CPP), was administered during the latter half of ECS
treatments. To minimize the effect of CPP on NMDAR ac-
tivation that was directly induced by ECS, CPP was injected
shortly after each ECS. This CPP treatment significantly
reversed the reduction of frequency facilitation at
14 days after 11 times of ECS (Fig. 8f ). Even a single
CPP injection after the last ECS was effective in reversing
the reduction of frequency facilitation (Fig. 8f). These
results suggest that the endogenous neuronal activity con-
tributes to the lasting change in the maturation-related
phenotype of GCs via NMDAR activation.
Discussion
Accumulating evidence suggests modifications of the mat-
uration status of brain neurons as a novel cellular basis of
treatments for psychiatric disorders [7, 8, 10–12, 20]. Here
we demonstrate that ECS profoundly changes biochemical
and physiological features of the mature dentate GCs:
ECS reduced the levels of mature neuronal markers, re-
duced activity-dependent neuronal responsiveness, and
increased somatic excitability in the dentate GCs, and
also reduced frequency facilitation of MF EPSPs. Since
the magnitude of MF frequency facilitation correlates
well with the expression level of the mature GC marker
Calb1, it can be a good physiological index of the func-
tional maturity of GCs [7]. After repeated ECS treat-
ments, the magnitude of facilitation was comparable to
that of control mice around postnatal day 10 [7]. The
rapid reduction in the expression of mature GC markers
after a single ECS and the lack of effects of X-ray irradi-
ation on the reduction of Calb1 expression indicated that
such “demature” GCs are distinct from newly generated
immature neurons. Immature GCs generally exhibit higher
input resistance than mature GCs, due to their small cell
size as indicated by small capacitance and also due to a
difference in the resting current density. In the present
study, ECS-treated GCs showed normal input resistance
and membrane capacitance (data not shown), suggesting
no significant change in the cell size. At the later stage of
GC maturation, the input resistance is inversely propor-
tional to the membrane capacitance [23], suggesting that
the cell size is the critical determinant of the input resist-
ance at late maturation of GCs. Therefore, a plausible inter-
pretation of our observations is that ECS can apparently
reverse some of the biochemical and physiological
Fig. 5 NMDA receptor activation and de novo protein synthesis are
involved in the rapid downregulation of maturation markers by ECS.
a, The relative expression of Calb1 in 5-HT4R-KO (-/-) mice at 6 h
after a single ECS (*** P < 0.001, Bonferroni’s post hoc test following
two-way ANOVA). b, The relative expression of Calb1 in mice treated
with 5,7-DHT (i.c.v.) at 6 h after a single ECS (*** P < 0.001, Bonferroni’s
post hoc test following two-way ANOVA). Veh: vehicle. c, The relative
expression of Calb1 and Tdo2 at 6 h after a single ECS in mice treated
with D-AP5 (1 μg/mouse, interaction [D-AP5 × ECS]; F(1,19) = 7.07 for
Calb1, # P < 0.05, F(1,19) = 15.7 for Tdo2, ### P < 0.001). d, The relative
expression of Calb1 and Tdo2 at 6 h after a single ECS in mice treated
with cycloheximide (Chx; 200 mg/kg, i.p., interaction [cycloheximide ×
ECS]; F(1,11) = 11.35 for Calb1, ### P < 0.001, F(1,11) = 149.1 for Tdo2,
## P < 0.01). Bonferroni’s post hoc test following two-way ANOVA,
*** P < 0.001, n.s., not significant. Sal: saline. The number (n) is
shown in the graph. Data are presented as means ± SEM
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alterations characterizing the late-stage maturation of GCs
without changing the overall morphology of them (Fig. 9).
We have previously shown that the SSRI antidepressant
fluoxetine can induce GC dematuration [7, 8, 10, 20]. The
phenotype of ECS-treated GCs investigated here resembled
those of the SSRI-treated demature GCs, as exemplified by
similar comprehensive gene expression profiles in the DG.
Since ECS has been considered to be an animal model of
the ECT used for depression, our results suggest that
dematuration of neurons in the DG could be a common
cellular basis for pharmacological and physical antidepres-
sant treatments. One of the common functional features of
the GCs found in SSRI- and ECS-treated mice is increased
somatic excitability. In addition, ECS-treated GCs show al-
teration of the synaptic E/I balance toward excitation. It has
been suggested that neuronal excitation or the E/I balance
in the DG is perturbed by chronic stress [27–29]. It is pos-
sible that GC dematuration restores neuronal activity in the
DG of individuals in a depressed state by enhancing the
synaptic and/or intrinsic excitability. Clinically, ECT has
fast-acting antidepressant effects and is effective in most of
patients who are resistant to monoaminergic antidepressant
drugs. Consistent with this clinical setting, the phenotypic
change in GCs by ECS emerges rapidly and does not re-
quire the serotonergic system. Although the magnitude of
dematuration, as assessed by the reduction of frequency fa-
cilitation, is on average similar between ECS and SSRI, the
effect of ECS is much less variable than that of SSRIs
(compare Fig. 3g in this study and Fig. 3b in [7]). In
SSRI-treated mice, the excessive change in the
maturation-related phenotype was accompanied by a
marked increase in day-to-day fluctuation of home-cage
activity levels that resembled an antidepressant-induced
rapid change in mood [8]. In addition, α-CaMKII hetero
KO mice show profound immaturity of the DG and in-
fradian oscillation of home-cage activity levels [2].
Thus, the invariable effect of ECS may be related to a
relatively low risk for switching to mania in patients
with bipolar disorder who are treated with ECT [30].
While ECT rapidly alleviates acute episodes of depression,
Fig. 6 Long-lasting phenotypic change in GCs after repeated ECS. a, b, The relative expression of Calb1 and Tdo2 at indicated time intervals after
single (a) or repeated (b) ECS (a, Tukey’s test following one-way ANOVA: F(2,9) = 54.21, *** P < 0.001 for Calb1, F(2,9) = 1048, *** P < 0.001 for Tdo2, b,
F(4,15) = 123, *** P < 0.001 for Calb1, F(4,15) = 53.67, *** P < 0.001 for Tdo2). c, Frequency facilitation tested at various time intervals after three or 11
times of ECS. d, The relative expression of Calb1 was compared between 5-HT4R-KO (-/-) mice and wild-type (+/+) mice at 14 days after 11 times
of ECS (*** P < 0.001, Bonferroni’s post hoc test following two-way ANOVA). e, The effect of X-ray (10 Gy) on the reduction of Calb1 at 14 days after
11 times of ECS. (** P < 0.01, Bonferroni’s post hoc test following two-way ANOVA). f, Representative images of immunoreactivity for doublecortin
in non-irradiated (ECS × 11) or irradiated (X-ray-ECS × 11) mice at 14 days after 11 times of ECS. Scale bar: 200 μm. The number (n) is shown in the
graph. Data are presented as means ± SEM
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relapse rates are relatively high after discontinuation of
the therapy [31, 32]. Based on our model, increased neur-
onal activity and/or augmentation of NMDAR activation
may help to prevent relapse of depressive symptoms after
discontinuation of ECT.
We demonstrated that the synaptic E/I balance is
changed toward excitation in the ECS-treated GCs,
and that the excitability of the ECS-treated GCs is con-
tinuously enhanced. Enhanced GABAergic inhibition
by diazepam after the period of ECS treatments par-
tially reversed the altered phenotype of GCs to the ini-
tial matured state (Fig. 7e), suggesting that endogenous
neuronal activity is required for lasting maintenance of
the demature state of GCs. Since block of NMDAR
activation during the non-stimulated period also atten-
uated the long-lasting effect of ECS on the phenotype
of GCs, it is likely that the enhanced synaptic excita-
tion of these cells supports their demature state via
NMDAR activation. Recent studies including our own
have suggested that both changes in the E/I balance
and aberrant neuronal maturation are involved in the
pathophysiological basis of schizophrenia and related
neuropsychiatric disorders [2, 5, 26, 33–36]. It is pos-
sible that defects in neuronal maturation could alter
the circuit E/I balance, and a change in the E/I balance
toward over-excitation may anchor the aberrant state
of maturation in these disorders. Enhanced inhibition
may benefit this type of psychiatric disorder, not only
by correcting the circuit E/I balance, but also by allow-
ing proper maturation of neurons in the circuit.
Indeed, enhancing GABAergic inhibition has been sug-
gested as a treatment strategy for schizophrenia [37].
Further investigation of the regulation of neuronal matur-
ation by neuronal activity would facilitate understanding
of the heterogeneous pathogenic and pathophysiological




Male C57BL/6J or C57BL/6N mice, 8 weeks of age, were
purchased from Japan SLC or Charles River Japan.
The 5-HT4 receptor mutant mice (strain name:
B6.129P2-Htr4 < tm1Dgen>/J > backcrossed to the C57BL/6J
background more than 10 times were purchased from
the Jackson Laboratory. Male and female homozygous
mutant mice and their wild-type littermates from
heterozygous mating were used in this study. Mice
were pair-housed and maintained under standard
conditions with a 12-h light/dark cycle and ad libitum
access to food and water unless otherwise stated. All
mice were habituated for over one week before experi-
mental procedures.
Electroconvulsive stimulation
Bilateral ECS (current, 25 mA; shock duration, 1 s; fre-
quency, 100 pulse/s; pulse width, 0.5 msec) was admin-
istered via moistened, spring-loaded ear-clip electrodes
Fig. 7 Augmentation of GABAergic signalling reverses long-lasting
phenotypic change. a, No significant difference was seen in frequent
facilitation at the MF synapse between mice treated with diazepam
(DZP, 5 mg/kg) and vehicle (Veh) for 3 weeks. b, Frequency facilitation at
14 days after 11 times of ECS in mice treated with 5 mg/kg diazepam or
vehicle (*** P < 0.001, Bonferroni’s test following two-way ANOVA,
interaction [drug treatment × ECS]; F(1,17) = 7.39, P = 0.0146). c, The
relative expression of Calb1 and Tdo2 at 1 day or 14 days after 11
times of ECS in mice treated with 10 mg/kg diazepam (Tukey’s test
following one-way ANOVA: F(2,6) = 122.1, *** P < 0.001 for Calb1,
F(2,6) = 90.9, * P < 0.05, *** P < 0.001 for Tdo2). d, Effects of diazepam
on frequency facilitation at 14 days after 11 times of ECS. Diazepam
(5 mg/kg) was administered during the period of ECS treatments
(t(10) = 4.062, P= 0.0097). e, Effects of diazepam (10 mg/kg) administered
after 11 times of ECS on the lasting reduction of frequency facilitation
(t(10) = 2.873, P= 0.0166). The number (n) is shown in the graph. Data are
presented as means ± SEM
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with a pulse generator (ECT Unit; Ugo Basile) to mice
that were anesthetized with isoflurane (1.5 to 2%) in
order to avoid sudden unexpected death associated with
seizures. In repeated treatments, ECS was administered 4
times a week for up to 3 weeks. The sham-treated animals
were handled in an identical manner to the ECS-treated
animals without the administration of shock. In cranial
irradiation experiments, ECS was started 14 day after
irradiation. Cranial X-ray irradiation was administered
as previously described [20]. X-ray (Rigaku Radiofrex
350 X-ray generator) at a dose of 10 Gy was delivered
at a dose rate of 0.74 Gy/min.
Drug treatments
Fluoxetine hydrochloride (LKT Labs) was dissolved in
drinking water and orally applied at a dose of 22 mg/kg/day
for 4 weeks as described previously [7]. The fluoxetine solu-
tions were prepared every day, and daily fluoxetine intake
was determined for individual mice on the basis of the
water consumption during the preceding 24 h and the
body weight measured every other day. Saccharin (0.2%)
was included in the fluoxetine solution to keep water intake
comparable to the baseline. Diazepam (Wako) was dis-
solved in dimethyl sulfoxide (DMSO) at 10 to 20 mg/ml,
diluted in the drinking water, and administered at 5 to
10 mg/kg/day. D-AP5 (Tocris Bioscience) was dissolved in
saline and intracerebroventricularly administered (1 μg/
mouse) under anesthesia with pentobarbital (50 mg/kg)
20 min prior to ECS. Cycloheximide (Santa Cruz) was
dissolved in saline and intraperitoneally administered at
a dose of 200 mg/kg 30 min before ECS. For deletion of
serotonergic neurons, 5,7-DHT (Sigma Aldrich) was
Fig. 8 Enhanced synaptic activation in GCs after repeated ECS. a, Left: A diagram showing the electrode arrangement for recording GC population
spikes (PSs) evoked by MPP stimulation. Right: Sample recordings of PSs evoked at three different intensities. Scale bars: 10 ms, 1 mV. b, Left: The
relationship between field EPSP slope and PS amplitude recorded in the GC layer after three times of ECS. Right: X-intercepts of linear regression lines
were measured to determine the threshold EPSP slope for evoking PS. (t(13) = 3.356, ** P= 0.0052, Student’s t-test with Welch’s correction, n represents
the number of slices). c, Threshold EPSP slope for evoking PS in absence and presence of picrotoxin (100 μM, PTX) in the same slices after three times of
ECS. A significant difference between CNT and ECS was observed only in the absence of PTX (Bonferroni’s test following two-way repeated measure
ANOVA; Saline, ** P< 0.01, interaction [drug treatment × ECS]; F(1,17) = 8.14, P= 0.011, n represents the number of slices). d, Left: A diagram showing the
electrode arrangement for recording evoked postsynaptic currents. Center: EPSCs and monosynaptic IPSCs recorded in the same GCs. Scale bars: 20 ms,
100 pA. Right: Reduced IPSC/EPSC ratios after three times of ECS (t(27) = 3.375, ** P= 0.0023, n represents the number of cells). e, Threshold EPSP slopes
for evoking PS at 14 days after 11 times of ECS (t(13) = 2.543, * P= 0.0245, n represents number of slices). f, Effect of CPP (1 or 5 treatments at 20 mg/kg)
injected after each ECS as indicated on frequency facilitation at 14 days after 11 times of ECS (1 treatment: t(11) = 2.73, * P = 0.0196, 5
treatments: t(8) = 4.293, ** P = 0.0026). The number (n) is shown in the graph. Data are presented as means ± SEM
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dissolved in saline containing 0.1% ascorbic acid and
was intracerebroventricularly administered (200 μg/mouse)
under anesthesia with pentobarbital (50 mg/kg) 30 min
after intraperitoneal injection of desipramine (25 mg/kg;
Sigma Aldrich). The deletion of serotonergic neurons
1 week after the injection was confirmed in equally con-
ditioned mice by immunohistochemical analysis using anti
5-HT antibody (Immunostar 20080, diluted 1:10000). CPP
(Sigma-Aldrich) was dissolved in saline and intraperitone-
ally injected at a dose of 20 mg/kg shortly after ECS
procedures.
Real time PCR
Mice were decapitated at the time indicated in figure
legends and the DG of the hippocampus was dissected
under a stereoscopic microscope. Total RNA was ex-
tracted from the isolated DG by using an RNeasy micro
kit (Qiagen) or Reliaprep RNA Cell Miniprep System
(Promega), and subjected to the reverse transcription
reaction with a Superscript VILO (Invitrogen), followed
by real time PCR with a LightCycler (Roche Applied
Science) using Fast Start DNA Master SYBR Green I.
Crossing point values were acquired by using the second
derivative maximum method. The expression level of
each gene was quantified using external standardized di-
lutions. Relative expression levels of target genes
between samples were normalized to that of 18S rRNA.
The specificity of each primer set was confirmed by
checking the product size by gel electrophoresis. Primer
sequences for each gene are shown in Table 5.
Immunohistochemistry
Mice were perfused with saline and 4% paraformaldehyde
in 0.1 M phosphate buffer, pH 7.4. The brains were
dissected out and postfixed in the same fixative at 4 °C for
24 h. After immersion in 0.1 M phosphate buffer contain-
ing 20% sucrose at 4 °C overnight, the brains were rapidly
frozen at -80 °C and sectioned using a cryostat at 30 μm
thickness. The free-floating sections were first incubated
with 10% normal equine serum in PBS containing 0.3%
Triton X-100 for 1 h at room temperature and subse-
quently incubated with mouse anti-calbindin-D-28 K
monoclonal antibody (Sigma Aldrich, C9848, diluted
1:3000), mouse anti-calretinin monoclonal antibody (Milli-
pore, MAB 1568, diluted 1:3000), goat anti-doublecortin
polyclonal antibody (Santa Cruz, sc-8066, diluted 1:500),
Fig. 9 Models of changes in maturation-related phenotypes of the adult GCs by ECS. Developmental stages of GCs in the DG can be identified
by stage marker expression and neuronal function
Table 5 Primer sequences used for real-time RT-PCR
Gene Forward Reverse
Calb1 5′- tctggcttcatttcgacgctg-3′ 5′- acaaaggatttcatttccggtga-3′
Tdo2 5′- atgagtgggtgcccgtttg-3′ 5′- ggctctgtttacaccagtttgag-3′
Dsp 5′- gctgaagaacactctagccca-3′ 5′- actgctgtttcctctgagaca-3′
Il1r1 5′- gtgctactggggctcatttgt-3′ 5′- ggagtaagaggacacttgcgaat-3′
Fos 5′- ctgtcaacacacaggactttt-3′ 5′- aggagatagctgctctactttg-3′
18S rRNA 5′- gaggccctgtaattggaatgag-3′ 5′- gcagcaactttaatatacgctattgg-3′
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rabbit anti-c-Fos polyclonal antibody (Calbiochem, PC38,
diluted 1:2000), or mouse anti-NeuN antibody (Millipore,
MAB377, diluted 1:500) overnight at 4 °C. After washing
three times with PBS containing 0.3% Triton X-100, the
sections were incubated with secondary antibody con-
jugated with AlexaFluor488 or AlexaFluor555 (Molecular
Probes). After washing, the sections were mounted on
slides and observed with a fluorescent microscope
(Biozero 8000, Keyence). For some sections of doublecortin
immunostaining, biotinylated horse anti-goat IgG (Vector)
was used as a secondary antibody, followed by incubation
with ABC Vectastain Kit (Vector). Antigen detection was
performed with 3,3′ -diaminobenzidine staining.
Electrophysiological analysis
Mice were singly housed in the institutional standard
condition (14:10 light/dark cycle; lights on at 6:00 A.M.
through 8:00 P.M.). Mice were decapitated under deep
halothane anesthesia 24 h after the last ECS unless
otherwise stated. Both hippocampi were isolated, and
transverse hippocampal slices (380 μm) were cut using a
tissue slicer. Electrophysiological recordings were per-
formed as described [7]. Recordings were made in a
submersion-type chamber maintained at 27.0–27.5 °C
and superfused at 2 ml/min with saline composed of (in
mM): NaCl, 125; KCl, 2.5; NaH2PO4, 1.0; NaHCO3, 26.2;
glucose, 11; CaCl2, 2.5; MgCl2, 1.3 (equilibrated with
95% O2/5% CO2). EPSPs arising from the MF synapses
were evoked by stimulating the dentate granule cell layer
and recorded from the stratum lucidum of CA3 using a
glass pipette filled with 2 M NaCl. The amplitude of
field EPSPs was measured on analysis as described [38].
A criterion used to identify the MF input was more than
85% block of EPSP by an agonist of group II metabotropic
glutamate receptors, (2S,2′R,3′R)-2-(2′,3′-dicarboxycyclo-
propyl)glycine (DCG-IV, 1 μM). Single electrical stimula-
tion was delivered at a frequency of 0.05 Hz unless
otherwise specified. For recording EPSPs and population
spikes evoked by activation of the MPP input to GCs, the
recording electrode was placed in the granule cell layer,
and electrical stimulation was delivered every 30 s via the
electrode placed in the middle third of the molecular
layer. The initial slope of EPSPs was measured on analysis.
The amplitude of the population spike was measured as
the difference between the negative peak and the average
of two positive peaks. Whole-cell current-clamp record-
ings were made from GCs with a pipette filled with a solu-
tion composed of (in mM) potassium gluconate 140,
HEPES 20, NaCl 8, MgATP 2, Na2GTP 0.3, EGTA 0.05
(pH adjusted to 7.3 with KOH). The recording pipette was
placed in the middle third of the granule cell layer.
Hyperpolarizing currents (6 - 16 pA, 400 ms) were
injected through the recording pipette to measure the
input resistance. Depolarizing currents (400 ms) with
increasing intensity by 10 pA steps were injected to
measure the threshold current intensity to evoke action po-
tentials. Whole-cell voltage-clamp recordings were made
from GCs with a pipette filled with a solution composed of
(in mM) cesium gluconate 140, HEPES 20, NaCl 8, EGTA
0.1, MgATP 2, Na2GTP 0.3 (pH adjusted to 7.3 with
CsOH). EPSCs evoked by MPP stimulation were recorded
at the reversal potential (-70 mV) for IPSCs. The amplitude
of EPSC was adjusted around 100 pA. Monosynaptic IPSCs
were then recorded in the same cells at +1 mV in the
presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX,
10 μM) and D-AP5 (25 μM). The liquid junction potential
was corrected in these recordings. All recordings were
made using a Multiclamp 700B amplifier (Molecular
Devices, Sunnyvale, CA, USA), filtered at 2 kHz and stored
in a personal computer via an interface (digitized at 5 -
10 kHz). DCG-IV and CNQX were purchased from Tocris
Bioscience (Bristol, UK). Picrotoxin was from Wako Pure
Chemical Industries, Ltd (Osaka, Japan).
In situ hybridization
In situ hybridization was performed using a digoxigenin
(DIG)-labeled riboprobe as described [39]. Calb1 cDNA
template probe was cloned by PCR with gene-specific
primers (Forward; 5′-actgaccacagcggcttc-3′, Reverse; 5′-
agaggcagaagcccatcc-3′, Product Length; 927 bp), verified
by sequencing, and used to produce a labeled riboprobe
with the RNA Labeling kit (Roche). The brains were re-
moved from mouse skulls at 6 h after single ECS and
rapidly frozen on dry ice. None of the sense probes
yielded any signal.
Microarray analysis
For comparison of gene expression profiles between
single ECS-treated and repeated ECS-treated DG, the
same RNA samples as in Fig. 2a and b were used. Dema-
tured DG and control samples were collected as follows.
Mice were decapitated at 24 h after the 11 times of ECS
or 4-week treatment of fluoxetine at a dose of 22 mg/kg.
The hippocampal slices were prepared as described
above. The dentate gyrus was dissected from some of
them, and the remaining slices were used for electro-
physiological analyses. Frequency facilitation at the MF-
CA3 synapse was measured in each mouse, and the DG
samples from fluoxetine-treated mice that exhibited
small frequency facilitation were used as dematured DG
(n = 3). Reduced facilitation was also confirmed in ECS-
treated mice. The control DG samples were collected from
vehicle- or sham-treated mice. Total RNA was extracted by
using an RNeasy micro kit (Qiagen) and the samples of the
same groups were put together. From each group, 100 ng
of total RNA was amplified with 3′IVT Express kit
(Affymetrix, Inc.). All samples were hybridized to the
GeneChip mouse genome 430A 2.0 array (Affymetrix, Inc.),
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and the microarray suite 5.0 of the Affymetrix gene chip
operating software was used for the analysis of the Gene-
Chip data. For each transcript represented on the array, the
statistical expression algorithm computes detection (present
or absent), signal intensity, change (increase or decrease),
and change p-value. For the comparison in the DG between
repeated ECS- and chronic fluoxetine-treatment, if the
average signal intensity in all of the conditions (ECS, sham,
fluoxetine, control) was lower than 50, the genes were
excluded from further analysis. Hippocampal gene expres-
sion data in Shn-2 KO mice and αCaMKII hetero KO
mice was obtained from [26] and [2], respectively.
Correlations were examined with Spearman correlation
coefficients. Gene ontology analysis was performed using
DAVID Bioinformatics Resources 6.8 (National Institute
of Allergy and Infectious Diseases).
Immunoblot
The brains were removed at 24 h after the last ECS and
the DG of the hippocampus was dissected under a
stereoscopic microscope. The isolated DG was sonicated
in protein lysis buffer containing protease inhibitor cock-
tail (Nacalai tesque) on ice and centrifuged at 20,000 g
for 10 min at 4 °C. Supernatants containing 10 μg of
proteins were separated on 12% SDS-polyacrylamide gel
by electrophoresis and transferred onto polyvinyl
difluoride membrane. The membrane was first blocked
with Blocking One (Nacalai tesque) for 1 h at room
temperature and then incubated with mouse anti-
calbindin-D-28 K monoclonal antibody (diluted 1:3000)
or anti-PSD-95 monoclonal antibody (BD bioscience,
BD610496, diluted 1:500) at 4 °C overnight. After wash-
ing, the membrane was incubated with horseradish per-
oxidase conjugated secondary antibody (Jackson) for
1 h at room temperature, and bands were visualized
with the ECL reagent (GE Healthcare). The same
membrane was then stripped, and detection of β-actin
was performed using mouse anti-β-actin monoclonal
antibody (Millipore, MAB1501R, diluted 1:3000) in the
same way. The signal intensity of calbindin was calcu-
lated by LAS-3000 (FujiFilm) and normalized to that of
β-actin.
Statistics
All data are presented as means ± SEM. Experiments
with two groups were compared with unpaired two-
tailed Student’s t test unless otherwise specified, and
experiments with more than two groups were subjected
to one-way ANOVA, followed by the Dunnett’s test or
the Tukey’s test. Interaction between subgroups was
compared with two-way ANOVA, followed by the
Bonferroni’s test. Statistical significance was set at
P < 0.05. The number of data “n” represents the number
of mice used unless otherwise specified.
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Additional file 1: Table S1. Functional classification of the genes that
showed reduced responsiveness 1 h after repeated ECS treatments
compared with a single ECS on the basis of the gene ontology (GO)
terms. Table S2. Functional classification of the genes that showed
similar responsiveness 1 h after repeated ECS treatments compared with
a single ECS on the basis of the GO terms. Table S3. Functional classification
of the genes that showed significantly increased expression change by only
ECS treatment (317 gene probes) on the basis of the gene ontology (GO)
terms. Table S4. Functional classification of the genes that showed
significantly decreased expression change by only ECS treatment (444
gene probes) on the basis of the GO terms. Table S5. Functional
classification of the genes that showed significantly increased expression
change by only SSRI treatment (690 gene probes) on the basis of the GO
terms. Table S6. Functional classification of the genes that showed
significantly decreased expression change by only SSRI treatment (739 gene
probes) on the basis of the GO terms. (PDF 169 kb)
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